Table 5.
Wide categories of COVID-19 vaccines that are currently (25 November 2021) in use according to their type and phase
| Vaccine | Type | Phase | Using in |
|---|---|---|---|
| Moderna | RNA-Based | Authorized | Canada, Israel, Switzerland, and the E.U., U.S., and U.K. |
| BioNTech/Pfizer | RNA-Based | Authorized | The European Commission and in Argentina, Mexico, Saudi Arabia, Canada, Bahrain, and the U.S. and U.K. |
| Oxford/AstraZeneca | Non-Replicating Viral Vector | Authorized | Argentina, Brazil, Dominican Republic, El Salvador, India, Mexico, Morocco, Pakistan, and the U.K. |
| Janssen Pharma | Non-Replicating Viral Vector | Authorized | For “emergency use” in the U.S. |
| Gamaleya Research Institute | Non-Replicating Viral Vector | Phase-III | Algeria, Argentina, Bolivia, Hungary, Palestine, Paraguay, Serbia, Turkmenistan, UAE, and Venezuela, and “registered” in Belarus and Russia. |
| CanSino Biologics | Non-Replicating Viral Vector | Phase-III | For “the Military” by China’s Central Military Commission. |
| Zydus Cadila Healthcare Limited | DNA-Based | Phase-III | For “emergency use” in India. |
| Research Institute for Biological Safety Problems | Inactivated Virus | Phase-III | Through “temporary registration” in Kazakhstan. |
| Wuhan Inst./Sinopharm | Inactivated Virus | Phase-III | For “emergency use” in China and the UAE. |
| Sinovac/Instituto Butantan | Inactivated Virus | Phase-III | For “emergency use” in Brazil, China, and Indonesia. |
| Beijing Inst./Sinopharm | Inactivated Virus | Phase-III | Bahrain, China, Pakistan, and the UAE. |
| Bharat Biotech | Inactivated Virus | Phase-III | For “emergency use” in India. |
| Shenzhen Kangtai Biological Products Co.,Ltd. | Inactivated Virus | Phase-III | For “emergency use” in China. |
| Chumakov Federal Scientific Center for Research and Development of Immune and Biological Products of the Russian Academy of Sciences | Inactivated Virus | Phase-III | As a “registered” vaccine in Russia. |
| Shifa Pharmed Industrial Co | Inactivated Virus | Phase-II/III | For “emergency use” in Iran. |
| Medigen Vaccine Biologics Corp/ NIAID/ Dynavax | Protein Subunit | Phase-III | For “emergency use” in Taiwan. |
| FBRI State Research Center of Virology and Biotechnology “VECTOR” | Protein Subunit | Phase-III | As a “registered” vaccine in Russia. |
| Anhui Zhifei Longcom Biopharmaceutical | Protein Subunit | Phase-III | For “emergency use” in China and Uzbekistan. |
| Vaxine Pty Ltd/ Flinders University/Oracle/ Medytox/ Sypharma/Oxford Expression Technologies | Protein Subunit | Phase-III | For “emergency use” in Iran. |
| Instituto Finlay de Vacunas | Protein Subunit | Phase-III | As part of a mass vaccination campaign in Cuba. |
| CIGB, Havana | Protein Subunit | Phase-III | As part of a mass vaccination campaign in Cuba. |
| Instituto Finlay de Vacunas | Protein Subunit | Phase-II | As a booster dose in Cuba. |